Stock market analysts and brokers have recently amended their target prices on shares of Karyopharm Therapeutics Inc. Leerink Swann reissued a buy rating and set a $18.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday, May 10th. They now have a United States dollars 12 price target on the stock.
Advertisement
The Company has received rating from WSJ analysts. They now have a Dollars 15 price target on the stock. Finally, Robert W. Baird began coverage on shares of Karyopharm Therapeutics in a research report on Monday, June 27th. Furthermore on May-27-16 the stock was “Initiated” by Raymond James from Outperform at $13. The ratio increased, as 11 funds sold all Karyopharm Therapeutics Inc shares owned while 15 reduced positions. They now have a Dollars 13 price target on the stock. The co for the one-month period ranked overweight by two analysts.
Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s average revenue estimates for the current quarter are $40K according to 9 number of analysts. They now have a Dollars 11 price target on the stock. They now own 19.84 million shares or 5.28% less from 20.95 million shares in 2016Q1. Karyopharm Therapeutics has been the topic of 14 analyst reports since September 2, 2015 according to StockzIntelligence Inc. JPMorgan Chase & Co. raised its position in Karyopharm Therapeutics by 29.0% in the first quarter. They now have a Dollars 42 price target on the stock. JMP Securities maintained it ^with/to4^ “Market Outperform” rating and $28 PT in March 9 note.
03/17/2015 – Karyopharm Therapeutics Inc. had its “outperform” rating reiterated by analysts at Oppenheimer.
Vertex Pharmaceuticals Incorporated’s (VRTX) price volatility for a month noted as 2.55% however its price volatility for a week documented as 3.38%. The ratio is more positive, as 40 investment managers increased and started new stock positions, while 26 sold and decreased stakes in Karyopharm Therapeutics Inc.
03/20/2014 – Karyopharm Therapeutics Inc. had its ” rating reiterated by analysts at RBC Capital. The share price is trading in a range of $7.53 – 9.86. (NASDAQ:KPTI) was up +36.66% during the last trading session, with a day high of 9.86. The company’s market capitalization is $350.17 million. The company has got a 52-week exceptional price of $19.41 and reached a 52-week lowest of the share price at $4.83.
Advertisement
Under Armour, Inc. (NYSE:UA), Maryland Governor Larry Hogan, MarylandSecretary of Commerce Mike Gill, Baltimore County Executive Kevin Kamenetz and Tradepoint Development Executive Vice President Eric Gilbert announced the company’s plan to open a 1.3 million square-foot distribution and warehouse facility atSparrows Point in Baltimore County, as part of the Tradepoint Atlantic redevelopment project. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. All of these efforts bring us ever closer to our goal of providing novel, first-in-class medicines to patients with cancer and other major diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibits the nuclear export protein XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies.
